Astec LifeSciences Past Earnings Performance
Past criteria checks 0/6
Astec LifeSciences's earnings have been declining at an average annual rate of -41.8%, while the Chemicals industry saw earnings growing at 14.6% annually. Revenues have been declining at an average rate of 2% per year.
Key information
-41.8%
Earnings growth rate
-41.8%
EPS growth rate
| Chemicals Industry Growth | 17.7% |
| Revenue growth rate | -2.0% |
| Return on equity | -35.5% |
| Net Margin | -27.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation Package
Jul 23
Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% Higher
Jul 03Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Mar 15Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital
May 17Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value
Oct 14We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease
Jul 27Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly
Jun 28A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)
Jun 03Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)
May 08Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 06Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)
Jan 25Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?
Dec 13We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet
Jul 21Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?
May 02The Trend Of High Returns At Astec LifeSciences (NSE:ASTEC) Has Us Very Interested
Apr 17Do Astec LifeSciences's (NSE:ASTEC) Earnings Warrant Your Attention?
Apr 02Is Astec LifeSciences Limited's (NSE:ASTEC) Shareholder Ownership Skewed Towards Insiders?
Mar 18Have Insiders Been Selling Astec LifeSciences Limited (NSE:ASTEC) Shares?
Mar 05Did You Miss Astec LifeSciences' (NSE:ASTEC) Whopping 481% Share Price Gain?
Feb 20A Look At Astec LifeSciences' (NSE:ASTEC) CEO Remuneration
Feb 08Declining Stock and Solid Fundamentals: Is The Market Wrong About Astec LifeSciences Limited (NSE:ASTEC)?
Jan 28What Does Astec LifeSciences Limited's (NSE:ASTEC) Share Price Indicate?
Jan 17
Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)
Jan 08I Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease
Dec 28Is Astec LifeSciences Limited (NSE:ASTEC) Popular Amongst Insiders?
Dec 18Revenue & Expenses Breakdown
How Astec LifeSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,729 | -1,036 | 614 | 0 |
| 30 Jun 24 | 3,852 | -785 | 638 | 0 |
| 31 Mar 24 | 4,586 | -469 | 629 | 0 |
| 31 Dec 23 | 4,317 | -509 | 610 | 0 |
| 30 Sep 23 | 4,981 | -258 | 579 | 0 |
| 30 Jun 23 | 5,871 | 60 | 557 | 0 |
| 31 Mar 23 | 6,285 | 256 | 533 | 0 |
| 31 Dec 22 | 7,735 | 736 | 571 | 0 |
| 30 Sep 22 | 8,297 | 975 | 586 | 0 |
| 30 Jun 22 | 7,325 | 883 | 550 | 0 |
| 31 Mar 22 | 6,769 | 899 | 513 | 0 |
| 31 Dec 21 | 5,803 | 708 | 447 | 0 |
| 30 Sep 21 | 5,230 | 531 | 418 | 0 |
| 30 Jun 21 | 5,754 | 619 | 402 | 0 |
| 31 Mar 21 | 5,587 | 650 | 394 | 0 |
| 31 Dec 20 | 5,698 | 723 | 379 | 0 |
| 30 Sep 20 | 5,786 | 774 | 354 | 0 |
| 30 Jun 20 | 5,639 | 648 | 331 | 0 |
| 31 Mar 20 | 5,287 | 475 | 309 | 0 |
| 31 Dec 19 | 4,844 | 291 | 280 | 0 |
| 30 Sep 19 | 4,781 | 269 | 274 | 0 |
| 30 Jun 19 | 4,507 | 331 | 263 | 0 |
| 31 Mar 19 | 4,382 | 357 | 262 | 0 |
| 31 Dec 18 | 4,246 | 402 | 261 | 0 |
| 30 Sep 18 | 3,781 | 374 | 248 | 0 |
| 30 Jun 18 | 3,611 | 325 | 235 | 0 |
| 31 Mar 18 | 3,676 | 349 | 229 | 0 |
| 31 Dec 17 | 3,254 | 212 | 236 | 0 |
| 30 Sep 17 | 3,119 | 148 | 228 | 0 |
| 30 Jun 17 | 3,008 | 192 | 226 | 0 |
| 31 Mar 17 | 2,987 | 191 | 213 | 0 |
| 31 Dec 16 | 3,167 | -29 | 188 | 0 |
| 30 Sep 16 | 2,865 | -114 | 193 | 0 |
| 30 Jun 16 | 2,643 | -206 | 182 | 0 |
| 31 Mar 16 | 2,330 | 50 | 163 | 0 |
| 31 Dec 15 | 2,629 | -115 | 282 | 2 |
| 30 Sep 15 | 2,777 | 61 | 254 | 2 |
| 30 Jun 15 | 2,728 | 84 | 129 | 0 |
| 31 Mar 15 | 2,669 | 148 | 134 | 0 |
| 31 Dec 14 | 2,212 | 131 | 218 | 3 |
| 30 Sep 14 | 2,147 | 127 | 217 | 3 |
| 30 Jun 14 | 2,156 | 96 | 117 | 0 |
| 31 Mar 14 | 2,070 | 87 | 212 | 3 |
| 31 Dec 13 | 2,179 | 97 | 184 | 5 |
Quality Earnings: ASTEC is currently unprofitable.
Growing Profit Margin: ASTEC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASTEC is unprofitable, and losses have increased over the past 5 years at a rate of 41.8% per year.
Accelerating Growth: Unable to compare ASTEC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASTEC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (8%).
Return on Equity
High ROE: ASTEC has a negative Return on Equity (-35.49%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Astec LifeSciences Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Asian Markets Securities Private Limited |
| Ankur Periwal | Axis Capital Limited |
| Satish Kumar | CGS International |